Last reviewed · How we verify
NCT04285944
Operator Radiation Protection During Cardiac Catheterization Using Mavig X-ray Protective Drapes®.
NA trial testing Mavig X-ray Protective Drapes in Radiation Exposure in 1,000 participants. Status unknown.
31 May 2020
Quick facts
| Lead sponsor | Universitaire Ziekenhuizen KU Leuven |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 1,000 |
| Start date | 1 October 2019 |
| Primary completion | 31 May 2020 |
| Estimated completion | 31 May 2020 |
| Sites | 2 locations across Belgium |
Drugs / interventions tested
- Mavig X-ray Protective Drapes
Conditions studied
- Radiation Exposure — all drugs for Radiation Exposure →
Sponsor
Universitaire Ziekenhuizen KU Leuven — full company profile →
Who can join
18 and older, any sex, with Radiation Exposure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Interventional cardiologists are exposed to significant doses of scatter radiation during cardiac catheterization and percutaneous coronary intervention. Traditional methods of reducing the radiation dose for operators in the cardiac catheterization laboratory include limiting the use of radiation, radiation protection aprons and shields, and the use of lead eye glasses. Despite these measures several parts of the operators body, including the head and neck, are poorly screened from scatter radiation. Radiation protection drapes have been developed for use in cardiac catheterization but no randomized controlled study has yet been performed with the commercially available Mavig X-ray Protective Drapes®. The aim of this study is to evaluate operator radiation protection using Mavig X-ray Protective Drapes®.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Efficacy of MAVIG X-Ray Protective Drapes in Reducing Operator Radiation Dose in the Cardiac Catheterization Laboratory: A Randomized Controlled Trial.
McCutcheon K, Vanhaverbeke M, Pauwels R, Dabin J, et al · · 2020 · cited 9× · PMID 33092401 · DOI 10.1161/circinterventions.120.009627 -
Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation.
McCutcheon K, Vanhaverbeke M, Dabin J, Pauwels R, et al · · 2021 · cited 6× · PMID 34987314 · DOI 10.1155/2021/3146104
Verify or expand the search:
- PubMed search for NCT04285944
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Radiation Exposure
Currently open trials in the same condition.
- NCT06875583 — The Radiation ProtEction for Dose RedUction in the Cardiac CathEter Lab Study: The REDUCE Trial · NA · recruiting
- NCT07008716 — Omitting CTV for Primary Tumor in LS-SCLC · Phase 3 · recruiting
- NCT06384105 — Study of the Patient Radiation Dose During Five Endourological Procedures · NA · recruiting
- NCT06360627 — Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT · NA · recruiting
- NCT05203250 — Longitudinal Registry Including Patients Treated With Heavy Particles · recruiting
Other Universitaire Ziekenhuizen KU Leuven trials
Trials by the same sponsor.
- NCT06831955 — LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer · Phase 2 · recruiting
- NCT07356505 — Efficacy and Safety of Micra AV2 Transcatheter Pacing System · NA · recruiting
- NCT07286968 — Gastro-Intestinal Digestion and Physiology After Bariatric Surgery · recruiting
- NCT06962137 — Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer · Phase 2 · recruiting
- NCT07270536 — Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04285944 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitaire Ziekenhuizen KU Leuven
- Last refreshed: 4 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04285944.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing